Investment Rating - The investment rating for the company is "Buy" [9]. Core Insights - The company's 2024 performance exceeded expectations, driven by the strong growth of its collagen stick product and the ramp-up of new products in the focus series, alongside the growth of its star product, Keli Jin [3][9]. - The company has a robust pipeline of new products in its cosmetics business, which is expected to contribute to future growth [3][9]. Financial Summary - The company's revenue for 2024 is projected to be 55.39 billion RMB, representing a year-on-year increase of 57%. The adjusted net profit is expected to be 21.51 billion RMB, up 47% year-on-year, while the net profit attributable to the parent company is forecasted at 20.62 billion RMB, a 42% increase [9]. - The gross profit margin for 2024 is estimated at 82.1%, a decrease of 1.5 percentage points year-on-year, primarily due to faster growth in the skincare segment compared to the medical device segment [9]. - The company’s sales expense ratio is expected to be 36.26%, an increase of 3.21 percentage points year-on-year, attributed to a higher proportion of online sales [9]. - The company anticipates a net profit margin of 37.2% for 2024, down 4 percentage points year-on-year, due to changes in channel and product structure [9]. Product and Brand Performance - The company’s star product, the collagen stick, maintains strong momentum, with significant contributions from new products and brand expansion. The focus series cream has generated over 200 million RMB in revenue, indicating successful product structure optimization [9]. - The Keli Jin brand is expected to see accelerated growth in the second half of 2024, benefiting from the strong performance of its flagship products [9]. - The company has a diverse product line and brand portfolio, which is expected to sustain rapid growth through continuous new product incubation [9].
巨子生物（02367）：2024年报点评：大单品引领品牌势能提升，多品线、品牌储备